Skip to main content

Table 3 Comparison of 20%-nonresponders vs. 20%-responders using the North American-derived equation

From: Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients

 

20%-nonrespondersa

20%-respondersa

P-value

 

Mean ± SE

Mean ± SE

 

Average of placebo run-in and randomization (Visits 0, 1, 2)

n = 212

n = 81

 

 EQ-5D at baseline

0.693 ± 0.005

0.698 ± 0.006

NS

Week 2 (Visit 3)

n = 207

n = 79

 

 Change from baseline, EQ-5D

0.003 ± 0.003

0.019 ± 0.006

0.02

 Change from baseline, ES

0.052 ± 0.054

0.300 ± 0.088

 

Week 6 (Visit 4)

n = 206

n = 79

 

 Change from baseline, EQ-5D

−0.002 ± 0.003

0.030 ± 0.005

<0.001

 Change from baseline, ES

−0.036 ± 0.051

0.483 ± 0.086

 

Week 10 (Visit 5)

n = 202

n = 76

 

 Change from baseline, EQ-5D

−0.008 ± 0.004

0.027 ± 0.006

<0.001

 Change from baseline, ES

−0.128 ± 0.055

0.435 ± 0.094

 

Week 14 (Visit 6)

n = 201

n = 78

 

 Change from baseline, EQ-5D

−0.016 ± 0.004

0.032 ± 0.007

<0.001

 Change from baseline, ES

−0.248 ± 0.062

0.515 ± 0.115

 

Week 16 (Visit 7)

n = 207

n = 79

 

 Change from baseline, EQ-5D

−0.026 ± 0.004

−0.007 ± 0.007

0.01

 Change from baseline, ES

−0.418 ± 0.065

−0.104 ± 0.110

 

Week 18 (Visit 8)

n = 203

n = 79

 

 Change from baseline, EQ-5D

−0.026 ± 0.004

−0.016 ± 0.007

NS

 Change from baseline, ES

−0.420 ± 0.061

−0.263 ± 0.108

 
  1. EQ-5D Euroqol 5-Dimension, ES effect size, NS not significant SE standard error, T25FW Time 25 Foot Walk.
  2. See Figure  1B for graphical representation.
  3. a20%-nonresponder or 20%-responder status based on whether the mean of all T25FW scores during double-blind visits improved by 20% or more from the mean of the T25FW scores during pre-randomization visits.